The securities of LF1 will commence quotation at 11:00 AM AEST on Friday, 27 June 2025. LF1 raised $300,000,000 pursuant to the offer under its product disclosure statement dated 26 May 2025 by the issue of 150,000,000 units at an issue price of $2.00 per unit. Today we begin another chapter with the launch of our La Trobe Private Credit Fund. This uniquely constructed, complementary portfolio aligns our core investment provide each Applicant with a supplementary or replacement product disclosure statement that corrects the deficiency and gives the Applicant the option to withdraw the Application within one month and be repaid the Application Amount. La Trobe Financial has launched its La Trobe Private Credit Fund. The Fund comprises a diversified private credit strategy, “targeting monthly distributions with a benchmark of RBA. It is important for you to consider the relevant Product Disclosure Statement (PDS) before deciding whether to invest, or to continue to invest, in a fund. Click here to view the PDSs and the Target Market Determinations or call us on 13 80 10 for a copy. It is important for you to consider the relevant Product Disclosure Statement (PDS) before deciding whether to invest, or to continue to invest, in a fund. Click here to view the PDSs and the Target Market Determinations or call us on 13 80 10 for a copy. The Initial Public Offering will seek to raise between $100m and $300m through the issue of units at a subscription price of $2.00. Please contact your appointed advisor for further information. Please click here for the Latrobe private credit fund Product Disclosure Statement. It is important you consider the Product Disclosure Statement (PDS) before deciding whether to invest or continue to invest in the fund. The PDS and Target Market Determination are available on our website. The fund has a minimum investment of $2,000. La Trobe said it will also look to prop up performance of the fund through regular off-market and on-market buy-backs – up to 5% of the capital each calendar quarter. The information in this PDS is general information only, it is not personal financial product advice and does not take into account your investment objectives, financial situation or particular needs.
Latest News
- wysoki estradiol w 3dc
- what is hydrocodone in spanish
- amoxicillin 500mg after tooth extraction
- tylenol blue and red
- can codeine cause false positive for morphine
- coumadin clinic fairbanks ak
- clindamycin dalacin c 300 mg
- buy strattera online cheap
- cialis price per pill 2012
- kamagra z internetu opinie
- does concerta have to be taken everyday
- lidocaine 2 oral solution
- lactose free milk good for babies
- lactose intolerance test melbourne
- soma edmond store hours
- bipolar ii disorder lamictal
- express scripts cialis prior
- relacion entre ambiente y ecologia
- lipitor allergic reaction itching
- xanax and 5 htp drug interactions